Top Page
Innovent Biologics
(OTC:1801)
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Innovent Biologics Business Overview & Revenue Model
Innovent Biologics Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 9.42B | 6.21B | 4.56B | 4.27B | 3.84B | Gross Profit |
| 7.91B | 4.40B | 3.63B | 3.70B | 3.46B | EBIT |
| -755.87M | -1.68B | -2.07B | -3.11B | -820.14M | EBITDA |
| -480.28M | -660.68M | -1.75B | -2.37B | -704.74M | Net Income Common Stockholders |
| -94.63M | -1.03B | -2.18B | -3.14B | -998.42M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 7.88B | 10.97B | 8.26B | 7.94B | 8.05B | Total Assets |
| 21.60B | 20.63B | 17.59B | 16.24B | 11.83B | Total Debt |
| 2.83B | 3.62B | 3.23B | 2.50B | 1.21B | Net Debt |
| -4.68B | -6.43B | 2.21B | 1.14B | -69.61M | Total Liabilities |
| 8.48B | 8.10B | 6.86B | 5.91B | 3.06B | Stockholders Equity |
| 13.12B | 12.53B | 10.73B | 10.33B | 8.78B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -1.24B | -3.30B | -3.87B | -1.08B | Operating Cash Flow |
| 0.00 | 147.81M | -1.92B | -2.02B | -307.69M | Investing Cash Flow |
| 0.00 | -998.66M | -1.44B | -2.70B | -5.18B | Financing Cash Flow |
| 0.00 | 2.59B | 2.89B | 5.00B | 4.91B |
Innovent Biologics Technical Analysis
Innovent Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $120.81B | ― | -0.72% | ― | 49.33% | 90.96% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
| $10.37B | 42.63 | 6.14% | 1.32% | ― | ― | ||
| $12.91B | 28.17 | 8.17% | ― | ― | ― | ||
72 Outperform | HK$24.70B | 27.86 | 31.65% | ― | 4.23% | 47.71% | |
54 Neutral | HK$32.35B | ― | -19.78% | ― | 25.96% | 39.58% | |
50 Neutral | HK$73.83B | ― | -8.98% | ― | -54.66% | -123.11% |
Innovent Biologics Corporate Events
Innovent Biologics reported a significant increase in product revenue for the first quarter of 2025, exceeding RMB2.4 billion, marking a growth of over 40% year-on-year. The company launched four new products, including Dovbleron, Limertinib, and Jaypirca in oncology, and SYCUME in general biomedicine, which contributed to the revenue growth. The inclusion of SINTBILO in the National Reimbursement Drug List and the launch of SYCUME for thyroid eye disease are seen as new growth drivers. Innovent’s strategic focus on sustainable growth and global innovation positions it for continued expansion in the biopharmaceutical industry.
Innovent Biologics has announced that its third-generation EGFR TKI, limertinib, has received approval from China’s National Medical Products Administration for first-line treatment of certain types of non-small cell lung cancer (NSCLC). This approval is based on positive results from a Phase 3 clinical trial, which demonstrated that limertinib significantly prolongs progression-free survival compared to gefitinib. The approval is expected to strengthen Innovent’s position in the oncology market and provide a new treatment option for patients with high-unmet needs.
Innovent Biologics, Inc. has announced changes in its board’s nomination committee and the designation of a lead independent non-executive director, effective March 31, 2025. Ms. Joyce I-Yin Hsu has been appointed as a member of the nomination committee, while Mr. Shuyun Chen has been designated as the lead independent non-executive director, reflecting the company’s ongoing efforts to strengthen its governance structure.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of both executive and independent non-executive directors, with Dr. De-Chao Michael Yu serving as the Chairman and CEO. This announcement underscores the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive edge in the biopharmaceutical sector.
Innovent Biologics, Inc. has updated the terms of reference for its Nomination Committee, which was originally established in 2018. The committee’s purpose is to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines in line with applicable laws and regulations. This update aims to ensure the committee’s operations align with the latest governance standards, potentially impacting the company’s strategic direction and governance practices.
Innovent Biologics, Inc. announced the grant of 4,023,697 share options to 49 grantees, including directors and non-connected employees, as part of its 2024 Share Scheme. The options, which have a ten-year validity period, are subject to a vesting schedule and performance targets for non-independent directors, while independent directors are exempt from these targets to maintain their objectivity. This move aligns with the company’s remuneration policy and aims to incentivize key personnel, potentially impacting the company’s operational efficiency and market competitiveness.
Innovent Biologics has reported a significant improvement in its financial performance for the year ended December 31, 2024, with a 51.8% increase in revenue and a substantial narrowing of its IFRS loss by 90.8% year-over-year. The company achieved its first-ever positive Non-IFRS profit and EBITDA, driven by robust product revenue growth, increased license fee income, and operational improvements, marking a historic milestone since its listing on the Hong Kong Stock Exchange.
Innovent Biologics has announced the approval of SYCUME®, China’s first IGF-1R monoclonal antibody, by the National Medical Products Administration for treating thyroid eye disease (TED). This approval marks a significant milestone as SYCUME® is the second IGF-1R antibody drug approved globally and offers a new treatment option for TED, which has lacked new therapies for 70 years in China. The drug demonstrated robust efficacy and safety in clinical trials, offering significant clinical and societal value by improving patient outcomes and redefining the standard of care for TED.
Innovent Biologics, Inc. has announced a board meeting scheduled for March 26, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact shareholder returns and reflect the company’s financial health.
Innovent Biologics announced that its new drug application for ipilimumab injection, combined with sintilimab, has been accepted by China’s National Medical Products Administration and granted Priority Review designation for treating colon cancer. This represents a significant milestone for Innovent, reinforcing its leadership in cancer immunotherapy. The acceptance is based on successful Phase 3 clinical trial results, which indicated improved pathologic complete response rates for patients, potentially reducing recurrence rates and improving long-term prognosis for those with MSI-H/dMMR colon cancer.
Innovent Biologics reported a robust revenue growth of over 40% in 2024, exceeding RMB8.2 billion, largely driven by its strong position in oncology and the successful launch of new products. Looking forward to 2025, the company plans to introduce six new drugs, including three novel oncology treatments, and capitalize on opportunities in chronic diseases. With its advancements in R&D and strategic market positioning, Innovent is confident in achieving its revenue target of RMB20 billion by 2027 and aims to continue its trajectory of sustainable growth and global innovation.